Is there an association between neurocognitive performance and medication adherence in first episode psychosis?
OBJECTIVE
Medication adherence is a determining factor for symptomatic remission and relapse prevention following a first episode of psychosis (FEP). Neurocognitive abilities have received only scant attention so far as a risk factor for poor adherence but significant impairments with memory and/or planning abilities could play a role. We examined early medication adherence following admission to a specialized clinical programme for FEP.


METHODS
One hundred sixty FEP participants and 35 healthy controls completed an exhaustive neurocognitive assessment. FEP participants were categorized as a function of their medication adherence at 6 months into poor (n = 34), partial (n = 27) and full (n = 99) adherence, respectively. Domain-specific and global measures of cognitive ability were examined.


RESULTS
No measure of neurocognition could significantly discriminate amongst the three medication adherence groups.


CONCLUSIONS
These results suggest no strong associations between neurocognitive abilities and medication adherence in first episode of psychosis.
Douglas Mental Health University Institute and Department of Psychiatry, McGill University, Montréal, Canada. martin.lepage@mcgill.ca
Martin
M
Lepage
Michael
M
Bodnar
Ridha
R
Joober
Ashok
A
Malla
D003071:Cognition; D005260:Female; D006801:Humans; D007361:Intelligence Tests; D008297:Male; D055118:Medication Adherence / Q000523:psychology*; D009483:Neuropsychological Tests; D011618:Psychotic Disorders / Q000175:diagnosis / Q000523:psychology*; D012720:Severity of Illness Index; D055815:Young Adult